Faron Pharma right in middle of fight against cancer and Coronavirus

  • Faron Pharma says study provides ‘compelling’ evidence cancer drug increases survival in patients with late-stage tumours
  • Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
  • Faron Pharma: City broker provides its commentary on Covid trial
  • Faron Pharmaceuticals’ update on balance sheet, Traumakine and Bexmarilimab

Quick facts: Faron Pharmaceuticals Oy


View company profile

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company’s investigational intravenous interferon beta-1a is a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland.

17 Sep 2021

(, ) said latest data from a phase I/II study of its cancer treatment bexmarilimab “strengthen our belief” it can increase survival in patients with a variety of late-stage solid tumours.

The updated results from the MATINS trial will be shared with delegates at the European Society for Medical Oncology later Friday in what’s called a proffered paper.

The audience will be told that median progression-free survival for those receiving Faron’s bexmarilimab was 59 days, while overall survival was 151 days.

A total of 83% of those who received three courses of treatment that achieved disease control rate status were still alive beyond six months.

Read more

26 Aug 2021

(, ) has confirmed that further clinical trials of its lead cancer asset will get underway in the fourth quarter after it showed “compelling antitumour activity” in multiple solid forms of the disease earlier in the process.

Bexmarilimab, which is undergoing phase I/II evaluations, is being developed as an immunotherapy candidate for hard-to-treat forms of the disease.

Read more

25 Aug 2021

(, ) Oy (First North:FARON) said researchers had begun dosing its first patient as part of a phase II/III trial of its lead asset in people fighting the effects of Covid.

Traumakine is an intravenous Interferon beta-1a that is also being developed for acute respiratory distress syndrome, severe kidney injury, cardiac protection and the prevention of solid organ transplant failure.

Read more

26 Jan 2021

Faron Pharmaceuticals Oy () is enjoying momentum with its project pipeline as its COVID-19 candidate Traumakine has just received the green light to enter the final stage of trials in the US.

The Finnish drugmaker will test it on people who have been hospitalised but do not yet need ventilation and have not received corticosteroids.

Read more

25 Aug 2021

The research team at broker Peel Hunt believes there is a role for intravenous interferon beta-1a (IFN beta-1a) treatments of the type being pioneered by Faron Pharmaceuticals () as a frontline approach for the effects of Covid.

The commentary followed on from the news that Faron has begun dosing patients for a phase II/III study to assess the efficacy of its IFN beta-1a formulation, Traumakine, in patients with the illness.

The asset is also being developed by Faron for the potential treatment of acute respiratory distress syndrome, severe kidney injury and cardiac protection.

Read more

26 Aug 2021

(, ) (AIM:FARN, ) () chief executive Dr Markku Jalkanen joins Proactive London’s Katie Pilbeam about the latest on its lead cancer asset Bexmarilimab and Traumakine, their acute respiratory distress syndrome and their financial position.

He confirms that the Bexmarilimab asset further trials will get underway in the fourth quarter and is being developed as an immunotherapy candidate for hard-to-treat forms of the disease.

Their half year results revealed company ended the six months to June 30 with EUR7.0mln in the bank and the firm posted a deficit for the period. The operating loss was EUR10.4mln.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


FTSE takes off ahead of international travel rule changes expected by the UK…

FTSE 100 made a decent start with airlines and travel groups leading the index higher on reports that the UK’s coronavirus travel arrangements will change today. London’s blue-chip index was up 18 at 7,045 in early trades.

UK retail sales recovered from a heavy fall in July but were still…

2 hours, 17 minutes ago

3 min read


Please enter your comment!
Please enter your name here